Beating-Heart Mitral Valve Repair Using a Novel ePTFE Cordal Implantation Device

Gammie, James S.; Bartuś, Krzysztof; Gackowski, Andrzej; D’Ambra, Michael N.; Szymański, Piotr; Bilewska, Agata; Kuśmierczyk, Mariusz; Kapelak, Bogusław; Rzucidło-Resil, Jolanta; Moat, Neil; Duncan, Alison; Yadev, Rashmi; Livesey, Steven; Diprose, Paul; Gerosa, Gino; D’Onofrio, Augusto; Pitterello, Demetrio; Denti, Paolo; Canna, Giovanni La; Bonis, Michele De; Alfieri, Ottavio; Hung, Judy; Kołsut, Piotr

doi:10.1016/j.jacc.2017.10.062

Cited by 80 publications

(74 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both are logically transapically implanted. Observational data reported low 30-day mortality (< 2%) but remaining MR grade ≥ 2 in 10 to 35% of patients after the procedure [25][26][27].…”

Section: Transcatheter Annuloplasty and Chordal Plastymentioning

confidence: 97%

Advances in transcatheter mitral and tricuspid therapies

Overtchouk

Piazza

Granada

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background: While rheumatic mitral stenosis has been effectively treated percutaneously for more than 20 years, mitral and tricuspid regurgitation treatment appear as a contemporary unmet need. The advent of transcatheter therapies offer new treatment options to often elderly and frail patients at high risk for open surgery. We aimed at providing an updated review of fast-growing domain of transcatheter mitral and tricuspid technology. Main body: We reviewed the existing literature on mitral and tricuspid transcatheter therapies. Mitraclip is becoming an established therapy for secondary mitral regurgitation in selected patients with disproportionately severe regurgitation associated with moderate left ventricle dysfunction. Evidence is less convincing for primary mitral regurgitation. Transcatheter mitral valve replacement is a promising emerging alternative to transcatheter repair, for secondary as well as primary mitral regurgitation. But further development is needed to improve delivery. Transcatheter tricuspid intervention arrives late after similar technologies have been developed for aortic and mitral valves and is currently at its infancy. This is likely due in part to previously under-recognized impact of tricuspid regurgitation on patient outcomes. Edge-to-edge repair is the most advanced transcatheter solution in development. Data on tricuspid annuloplasty and replacement is limited, and more research is warranted. Conclusion: The future appears bright for transcatheter mitral therapies, albeit their place in clinical practice is yet to be clearly defined. Tricuspid transcatheter therapies might address the unmet need of tricuspid regurgitation treatment.

show abstract

“…Both are logically transapically implanted. Observational data reported low 30-day mortality (< 2%) but remaining MR grade ≥ 2 in 10 to 35% of patients after the procedure [25][26][27].…”

Section: Transcatheter Annuloplasty and Chordal Plastymentioning

confidence: 97%

Advances in transcatheter mitral and tricuspid therapies

Overtchouk

Piazza

Granada

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…37,38 The NeoChord (NeoChord Inc, St Louis Park, MN) and Harpoon (Harpoon Medical, Baltimore, MD) device system are 2 devices that have undergone limited clinical trials for minimally invasive mitral chordal repair. 39,40 Both devices represent intermediate step toward percutaneous repair; however, more clinical data are needed to show their potential long-term benefits in high risk patients. [39][40][41]…”

Section: Transcatheter Mitral Valve Repairmentioning

confidence: 99%

“…39,40 Both devices represent intermediate step toward percutaneous repair; however, more clinical data are needed to show their potential long-term benefits in high risk patients. [39][40][41]…”

Section: Transcatheter Mitral Valve Repairmentioning

confidence: 99%

The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2019

Evans¹,

Weiner

Shaefi

et al. 2020

Journal of Cardiothoracic and Vascular Anesthesia

View full text Add to dashboard Cite

This highlights in our specialty for 2019 begin with the ongoing major developments in transcatheter valve interventions. Thereafter, the advances in left ventricular assist devices are reviewed. The recent focus on conduit selection and robotic options in coronary artery bypass surgery are then explored. Finally, this special articles closes with a discussion of pulmonary hypertension in noncardiac surgery, anesthetic technique in cardiac surgery, as well as postoperative pneumonia and its outcome consequences.

show abstract

“…In an early feasibility trial in patients with degenerative MR and posterior leaflet prolapse, the Harpoon device has been investigated (28). The Harpoon TSD-5 (Edwards Lifesciences, Irvine, USA) device is a 14F system designed for transapical multiple PTFE implantation.…”

Section: Harpoon Tsd-5 (Edwards Lifescience Usa)mentioning

confidence: 99%

Transcatheter mitral valve chord repair

Savić

Pozzoli

Gülmez

et al. 2018

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

The field of mitral valve disease diagnosis and management is rapidly evolving. New understanding of pathophysiology and improvements in the adoption of sophisticated multimodality imaging modalities have led to early diagnosis and to more complex treatment. The most common cause of mitral regurgitation (MR) in the western world is in the primary alteration of the valve, which leads to degenerative leaflet prolapse due to chordal elongation or rupture and annular dilatation. Untreated, significant MR has a negative impact prognosis, leading to reduction of survival. In the setting of degenerative MR, surgical repair currently represents the standard of care. Treatment of asymptomatic patients with severe MR in the Valve Center of Excellence, in which successful repair reaches more than 95% and surgical mortality less than 1%, symbolizes the direction for the next years. Transcatheter mitral valve repair with different devices, more recently the chordal replacement ones, is providing good outcomes and became a therapeutic option in highrisk patients with degenerative MR. In the future, more advances are expected from further development of interventional techniques, careful evaluation and better patient selection. This review will focus on long-term surgical outcomes of mitral valve repair with artificial chordae and on the emerging transcatheter chordal repair devices as therapeutic options for degenerative MR patients.

show abstract

Beating-Heart Mitral Valve Repair Using a Novel ePTFE Cordal Implantation Device

Cited by 80 publications

References 26 publications

Advances in transcatheter mitral and tricuspid therapies

Advances in transcatheter mitral and tricuspid therapies

The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2019

Transcatheter mitral valve chord repair

Contact Info

Product

Resources

About